Literature DB >> 31694367

Quantitative Analysis of Transferrin Receptor 1 (TfR1) in Individual Breast Cancer Cells by Means of Labeled Antibodies and Elemental (ICP-MS) Detection.

Mario Corte-Rodríguez1,2, Elisa Blanco-González1,2, Jörg Bettmer1,2, María Montes-Bayón1,2.   

Abstract

Cells are able to precisely control the amount of iron they acquire in the form of transferrin (TF)-bound iron by modulating the synthesis of transferrin receptor 1 (TfR1). In tumor cells, elevated TfR1 seems to be related to poorer outcome for patients. Thus, the direct measurement of this biomarker in breast cancer tissues and cells might serve as a prognosis biomarker. In this work, we have used Nd-labeled antibodies to tag the TfR1 present on the cell surface of two cell models of breast cancer with different malignancy (MCF7 and MDA-MB 231). For this aim, monoclonal antibody anti-TfR1 is first labeled with a polymeric chelator (MAXPAR) with the subsequent incorporation of several isotopic 143Nd atoms. The characterization of the labeled antibody revealed a stoichiometry of 21 Nd atoms per antibody molecule that can be used for further quantification experiments. This antibody is used for cell tagging followed by single-cell analysis using inductively coupled plasma mass spectrometry (ICP-MS) detection. In this case, cell introduction is conducted using a high-efficiency nebulizer and spray chamber to achieve transport efficiencies of up to 55% for cells. Quantitative results revealed a number of receptors per cell significantly higher in the case of the most malignant phenotype (MDA-MB-231). Absolute and relative TfR1 concentration values are obtained in individual cells for the first time using the proposed system.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31694367     DOI: 10.1021/acs.analchem.9b03438

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  7 in total

Review 1.  Living in a transient world: ICP-MS reinvented via time-resolved analysis for monitoring single events.

Authors:  M Resano; M Aramendía; E García-Ruiz; A Bazo; E Bolea-Fernandez; F Vanhaecke
Journal:  Chem Sci       Date:  2022-03-14       Impact factor: 9.969

2.  Phenazine derivatives attenuate the stemness of breast cancer cells through triggering ferroptosis.

Authors:  Yue Yang; Yuanyuan Lu; Chunhua Zhang; Qianqian Guo; Wenzhou Zhang; Ting Wang; Zhuolu Xia; Jing Liu; Xiangyu Cheng; Tao Xi; Feng Jiang; Lufeng Zheng
Journal:  Cell Mol Life Sci       Date:  2022-06-11       Impact factor: 9.207

3.  Doxorubicin-transferrin conjugate alters mitochondrial homeostasis and energy metabolism in human breast cancer cells.

Authors:  Paulina Wigner; Krzysztof Zielinski; Magdalena Labieniec-Watala; Agnieszka Marczak; Marzena Szwed
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

4.  Engineered Human Heavy-Chain Ferritin with Half-Life Extension and Tumor Targeting by PAS and RGDK Peptide Functionalization.

Authors:  Shuang Yin; Yan Wang; Bingyang Zhang; Yiran Qu; Yongdong Liu; Sheng Dai; Yao Zhang; Yingli Wang; Jingxiu Bi
Journal:  Pharmaceutics       Date:  2021-04-09       Impact factor: 6.321

5.  Cisplatin Uptake in Macrophage Subtypes at the Single-Cell Level by LA-ICP-TOFMS Imaging.

Authors:  Anna Schoeberl; Michael Gutmann; Sarah Theiner; Martin Schaier; Andreas Schweikert; Walter Berger; Gunda Koellensperger
Journal:  Anal Chem       Date:  2021-11-30       Impact factor: 6.986

6.  Fundamental studies on droplet throughput and the analysis of single cells using a downward-pointing ICP-time-of-flight mass spectrometer.

Authors:  Thomas Vonderach; Detlef Günther
Journal:  J Anal At Spectrom       Date:  2021-11-22       Impact factor: 4.023

7.  Role of TFRC as a Novel Prognostic Biomarker and in Immunotherapy for Pancreatic Carcinoma.

Authors:  Cheng Yang; Junqiang Li; Yongdong Guo; Dongxue Gan; Chao Zhang; Ronglin Wang; Lei Hua; Liaoliao Zhu; Peixiang Ma; Jingjie Shi; Shanshan Li; Haichuan Su
Journal:  Front Mol Biosci       Date:  2022-03-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.